Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
ImmunityBio, Inc. (IBRX)
Company Research
Source: GlobeNewswire
LOS ANGELES, April 07, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 26, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR IMMUNITYBIO INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On March 24, 2026, Bloomberg reported that ImmunityBio had received a Warning Letter from the U.S. Food and Drug Administration (“FDA”) stating that the Company’s Executive Chairman and Global Chief Scientific and Medical Officer, Patrick Soon-Shiong, made inaccurate claims on a podcast regarding the Company’s lead biologic product, Anktiva, including that the drug “can cure and even prevent all canc
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff RoleBusiness Wire
- INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens BermanGlobeNewswire
- ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitPR Newswire
- Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire
- INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action LawsuitPR Newswire
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 4/6/26 - Form 8-K
- 4/2/26 - Form 4
- 3/31/26 - Form 8-K
- IBRX's page on the SEC website